Abstract
METEORA-II was designed to test the concept of the metronomic VEX regimen administered for as long as the pt has the possibility of deriving a benefit from it, in comparison with weekly P, for pts with ER+/HER2- MBC candidates for chemotherapy (CT). Time to treatment failure (TTF) was chosen as primary endpoint, as CT may be stopped due to lack of tolerability, lack of efficacy or pt preference.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
